A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

NCT01128894 on ClinicalTrials.gov · last registry update 2017-02-23

Finished September 2011, after enrolling 841 people. Primary outcome, as filed: Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 841
Started: 2010-05
Primary completion: 2011-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.